A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease

  1. Navas-López, V.M.
  2. Pujol Muncunill, G.
  3. Llerena, E.
  4. Navalón Rubio, M.
  5. Gil-Ortega, D.
  6. Varea-Calderón, V.
  7. Sierra Salinas, C.
  8. Martin-de-Carpi, J.
Revista:
Anales de Pediatria

ISSN: 1695-9531 1695-4033

Any de publicació: 2018

Volum: 88

Número: 2

Pàgines: 89-99

Tipus: Article

DOI: 10.1016/J.ANPEDI.2017.01.013 GOOGLE SCHOLAR lock_openAccés obert editor